Royal Bank of Canada
OCUL icon

Royal Bank of Canada’s Ocular Therapeutix OCUL Stock Holding History

Royal Bank of Canada’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Buy
26,554
+16,902
+175% +$161K ﹤0.01% 4653
2025
Q4 		$117K Sell
9,652
-385,867
-98% -$4.69M ﹤0.01% 5117
2025
Q3 		$4.62M Buy
395,519
+3,765
+1% +$45K ﹤0.01% 2742
2025
Q2 		$3.63M Buy
391,754
+389,045
+14,361% +$3.05M ﹤0.01% 2834
2025
Q1 		$20K Sell
2,709
-3,331
-55% -$25.6K ﹤0.01% 5929
2024
Q4 		$51K Sell
6,040
-12,681
-68% -$124K ﹤0.01% 5683
2024
Q3 		$163K Buy
18,721
+1,554
+9% +$12.8K ﹤0.01% 4987
2024
Q2 		$117K Buy
17,167
+14,578
+563% +$90K ﹤0.01% 5171
2024
Q1 		$24K Sell
2,589
-21,503
-89% -$153K ﹤0.01% 5845
2023
Q4 		$107K Sell
24,092
-145,680
-86% -$431K ﹤0.01% 5582
2023
Q3 		$534K Buy
169,772
+4,717
+3% +$19.3K ﹤0.01% 3987
2023
Q2 		$852K Sell
165,055
-19,257
-10% -$115K ﹤0.01% 3510
2023
Q1 		$971K Buy
184,312
+174,942
+1,867% +$831K ﹤0.01% 3362
2022
Q4 		$26K Buy
9,370
+4,132
+79% +$13.7K ﹤0.01% 6194
2022
Q3 		$22K Buy
5,238
+4,304
+461% +$21.7K ﹤0.01% 6103
2022
Q2 		$4K Sell
934
-67,609
-99% -$255K ﹤0.01% 6741
2022
Q1 		$339K Sell
68,543
-20,628
-23% -$114K ﹤0.01% 4615
2021
Q4 		$622K Buy
89,171
+7,894
+10% +$61.3K ﹤0.01% 4279
2021
Q3 		$812K Buy
81,277
+3,282
+4% +$36.9K ﹤0.01% 3903
2021
Q2 		$1.11M Sell
77,995
-1,707
-2% -$25.9K ﹤0.01% 3564
2021
Q1 		$1.31M Sell
79,702
-6,080
-7% -$117K ﹤0.01% 3347
2020
Q4 		$1.77M Sell
85,782
-7,012
-8% -$104K ﹤0.01% 3025
2020
Q3 		$706K Sell
92,794
-29,752
-24% -$247K ﹤0.01% 3564
2020
Q2 		$1.02M Sell
122,546
-7,976
-6% -$52.9K ﹤0.01% 3154
2020
Q1 		$646K Sell
130,522
-22,958
-15% -$113K ﹤0.01% 3395
2019
Q4 		$606K Sell
153,480
-1,801
-1% -$6.26K ﹤0.01% 3840
2019
Q3 		$472K Buy
155,281
+7,803
+5% +$34.9K ﹤0.01% 3877
2019
Q2 		$648K Buy
147,478
+39,218
+36% +$145K ﹤0.01% 3675
2019
Q1 		$430K Sell
108,260
-16,375
-13% -$65.8K ﹤0.01% 3832
2018
Q4 		$496K Buy
124,635
+22,985
+23% +$127K ﹤0.01% 3702
2018
Q3 		$700K Buy
101,650
+16,077
+19% +$101K ﹤0.01% 3665
2018
Q2 		$578K Buy
85,573
+3,699
+5% +$25.4K ﹤0.01% 3681
2018
Q1 		$533K Sell
81,874
-1,509
-2% -$8.49K ﹤0.01% 3659
2017
Q4 		$371K Sell
83,383
-80,678
-49% -$412K ﹤0.01% 3999
2017
Q3 		$1.01M Sell
164,061
-39,497
-19% -$254K ﹤0.01% 3206
2017
Q2 		$1.89M Buy
203,558
+5,853
+3% +$56.7K ﹤0.01% 2629
2017
Q1 		$1.83M Buy
197,705
+24,331
+14% +$203K ﹤0.01% 2608
2016
Q4 		$1.45M Buy
173,374
+77,959
+82% +$605K ﹤0.01% 2834
2016
Q3 		$655K Buy
95,415
+46,205
+94% +$282K ﹤0.01% 3485
2016
Q2 		$244K Buy
49,210
+46,200
+1,535% +$458K ﹤0.01% 4267
2016
Q1 		$29K Buy
3,010
+243
+9% +$1.84K ﹤0.01% 5355
2015
Q4 		$26K Sell
2,767
-662
-19% -$7.15K ﹤0.01% 5602
2015
Q3 		$48K Buy
3,429
+1,528
+80% +$30.7K ﹤0.01% 5150
2015
Q2 		$40K Buy
1,901
+1,470
+341% +$36.4K ﹤0.01% 5355
2015
Q1 		$18K Sell
431
-308
-42% -$10.1K ﹤0.01% 5392
2014
Q4 		$17K Sell
739
-2,911
-80% -$49K ﹤0.01% 5457
2014
Q3 		$55K Buy
+3,650
New +$54K ﹤0.01% 4900

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Royal Bank of Canada's OCUL Position: Q1 2026 in Review

Royal Bank of Canada increased its Ocular Therapeutix (OCUL) stake by 175% in Q1 2026, buying an estimated $161K and bringing the position to 26,554 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #4653.

Royal Bank of Canada first reported a position in OCUL in Q3 2014 and has held it in 47 quarters since. The position peaked at $4.62M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Royal Bank of Canada held 26,554 shares of Ocular Therapeutix worth $225K as of Q1 2026.
  • Royal Bank of Canada bought 16,902 Ocular Therapeutix shares in Q1 2026, an estimated $161K.
  • Ocular Therapeutix made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4653 holding.
  • Royal Bank of Canada first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 47 quarters since.
  • Royal Bank of Canada's Ocular Therapeutix position peaked at $4.62M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.